We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lower Cut-Off Point of Blood Glucose May Define Prediabetes

By LabMedica International staff writers
Posted on 15 Dec 2016
Doctors define prediabetes as impaired fasting glucose with a higher than normal blood sugar levels after a period of fasting, impaired glucose tolerance with a higher than normal blood sugar levels after eating, or raised glycosylated hemoglobin levels.

Results of studies on the association between prediabetes and risk of cardiovascular disease and all-cause mortality are also inconsistent. More...
Furthermore, whether raised glycosylated hemoglobin levels for defining prediabetes is useful for predicting future cardiovascular disease is unclear.

Scientists affiliated with the Affiliated Hospital at Shunde, (Southern Medical University, Foshan, China) analyzed the results of 53 studies involving over 1.6 million individuals to shed more light on associations between different definitions of prediabetes and the risk of cardiovascular disease, coronary heart disease, stroke, and all-cause mortality.

Prediabetes was defined as impaired fasting glucose according to the criteria of the American Diabetes Association (ADA, Arlington County, VA, USA; IFG-ADA; fasting glucose 5.6-6.9 mmol/L), the World Health Organization expert group (WHO, Geneva, Switzerland; IFG-WHO; fasting glucose 6.1-6.9 mmol/L), impaired glucose tolerance (two hour plasma glucose concentration 7.8-11.0 mmol/L during an oral glucose tolerance test), or raised hemoglobin A1c (HbA1c) of 39-47 mmol/mol (5.7-6.4%) according to ADA criteria or 42-47 mmol/mol (6.0-6.4%).

The scientists found that prediabetes, defined as impaired fasting glucose or impaired glucose tolerance, was associated with an increased risk of cardiovascular disease and all-cause mortality. The risk increased in people with a fasting glucose concentration as low as 5.6 mmol/L (100.8 mg/dL), which was the lower cut-off point according to ADA criteria. Raised HbA1c levels to 39-47 mmol/mol or 42-47 mmol/mol were both associated with an increased risk of composite cardiovascular disease and coronary heart disease but not with an increased risk of stroke and all-cause mortality.

The authors concluded that prediabetes, defined as impaired glucose tolerance, impaired fasting glucose, or raised HbA1c, was associated with an increased risk of cardiovascular disease. The health risk might be increased in people with a fasting glucose concentration as low as 5.6 mmol/L or HbA1c of 39 mmol/mol. The study was published on November 23, 2016, in the journal BMJ.

Related Links:
Southern Medical University
American Diabetes Association
World Health Organization

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.